Spots Global Cancer Trial Database for omacetaxine mepesuccinate
Every month we try and update this database with for omacetaxine mepesuccinate cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate | NCT01844869 | Hematologic Mal... Solid Tumors | omacetaxine mep... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation | NCT00375219 | Chronic Myeloid... | Omacetaxine mep... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia | NCT00003239 | Leukemia | Recombinant Int... Cytarabine Omacetaxine Mep... | 12 Years - | M.D. Anderson Cancer Center | |
| Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation | NCT00375219 | Chronic Myeloid... | Omacetaxine mep... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT02029417 | Acute Myeloid L... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Secondary Acute... Untreated Adult... | cytarabine omacetaxine mep... decitabine laboratory biom... | 65 Years - | Roswell Park Cancer Institute | |
| Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase | NCT00003694 | Chronic Myeloge... Chronic Phase C... | omacetaxine mep... cytarabine laboratory biom... | 16 Years - | National Cancer Institute (NCI) | |
| Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 | NCT04874194 | Hematopoietic a... Recurrent Acute... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Acut... Refractory Myel... | Omacetaxine Mep... Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 | NCT04874194 | Hematopoietic a... Recurrent Acute... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Acut... Refractory Myel... | Omacetaxine Mep... Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase | NCT00003694 | Chronic Myeloge... Chronic Phase C... | omacetaxine mep... cytarabine laboratory biom... | 16 Years - | National Cancer Institute (NCI) | |
| Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML | NCT00462943 | Chronic Myeloid... | Omacetaxine mep... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia | NCT00003239 | Leukemia | Recombinant Int... Cytarabine Omacetaxine Mep... | 12 Years - | M.D. Anderson Cancer Center | |
| Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia | NCT00002574 | Leukemia | recombinant int... omacetaxine mep... | 15 Years - | National Cancer Institute (NCI) | |
| Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML | NCT00462943 | Chronic Myeloid... | Omacetaxine mep... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
